* Calgene Inc., of Davis, Calif., was issued U.S. patent No.5,370,996, covering Jojoba reductase gene, which is a plant oilsmodification gene used in rapeseeds to boost production of longchain liquid waxes, which are used to make cosmetics and lubricants.
* Exogen Inc., of West Caldwell, N.J., was issued U.S. patent No.5,376,065, titled "Non-invasive method and means for in-vivo bonegrowth stimulation." It is the fourth in a series of patents aimed atpreventing bone loss.
* GeneMedicine Inc., of The Woodlands, Texas, said U.S. patent No.5,374,544, titled "Mutated skeletal actin promoter," was issued toBaylor College of Medicine in Houston. GeneMedicine has anexclusive license for the patent in gene therapy.
* GeneType AG, of Zug, Switzerland, was issued U.S. patent No.5,192,659, titled "Intron sequence analysis method for detection ofadjacent and remote alleles as haplotypes." The patent, whichinvolves a process of determining haplotype without knowledge offamily gene inheritance, is specific for the HLA gene onchromosome 6.
* Isis Pharmaceuticals Inc., of Carlsbad, Calif., was issued U.S.patent No. 5,378,825, titled "Backbone modified oligonucleotideanalogs," covering oligonucleosides that have chemically modifiedbackbones in which non-phosphate linkages replace phosphatelinkages.
* Mycogen Corp., of San Diego, was issued U.S. patent No.5,380,831, for the synthesis of Bacillus thuringiensis bacterial genesto enhance expression of plant proteins that kill insects.
* Prototek Inc., of Dublin, Calif., was issued U.S. patent No.5,374,623, titled "Peptidyl activated ketone inhibitors containingnatural and unnatural peptide sequences." The patent is for use indevelopment of the company's cysteine protease inhibitors.
* Sepracor Inc., of Marlborough, Mass., was issued U.S. patent No.5,375,693, covering use of terfenadime carboxylate, the activemetabolite form of terfenadime, a drug approved by the FDA andmarketed by Marion Merrell Dow Inc., of Kansas City, Mo.
* Xoma Corp., of Berkeley, Calif., was issued U.S. patent No.5,376,546 covering analogs for recombinant DNA-derived gelonin, aribosome inactivating enzyme for potential use in treatingautoimmune and infectious diseases and cancer.
(c) 1997 American Health Consultants. All rights reserved.